|
|
|
|
|
|
||
|
|
||||
|
|
||||
|
||||
Preclinical Experimental Therapeutics |
Children's Hospital of Philadelphia, Division of Neuro-oncology (B.G., C.-B.T., P.C.P.) and Department of Neurosurgery (S.M., L.N.S.), Philadelphia, PA 19104; and The Wistar Institute (A.C., S.V., D.S.), Hospital of the University of Pennsylvania, Department of Neurosurgery (K.D.J.), Philadelphia, PA 19104
2 Address correspondence and reprint requests to Peter C. Phillips, Children's Hospital of Philadelphia, Division of Neuro-Oncology, 3400 Civic Center Boulevard, Philadelphia, PA 19104.
Abstract
Malignant glioma in adults and primitive neuroectodermal tumors/medulloblastomas in children are the most common malignant primary brain tumors that either respond poorly to current treatment or tend to recur. Adoptive therapy with TALL-104 cells—an IL-2-dependent, major histocompatibility complex nonrestricted, cytotoxic T-cell line—has demonstrated significant antitumor activity against a broad range of implanted or spontaneously arising tumors. This study investigates distribution of systemically and locally administered TALL-104 cells and their efficacy in effecting survival of a rat model of human brain tumor. In vitro, TALL-104 cells showed significant cytotoxic activity when added to human glioblastoma cell lines U-87 MG, U-251 MG, and A1690; the medulloblastoma cell lines DAOY, D283 Med, and D341 Med; and the epidermoid cancer cell line A431. In brain tumor-bearing rats, the amount of fluorescent dye-labeled TALL-104 cells in brain increased after they were given by intracarotid injection as compared with i.v. cell administration. However, TALL-104 cells rapidly decreased to low levels within 1 h after intracarotid injection. This finding suggests that TALL-104 cells given systemically may not invade brain or tumor tissues, but rather may remain in the vascular system, making this approach less efficient for brain tumor treatment. In a model of athymic rats engrafted with human A431 carcinoma brain tumor, repetitive local administration of TALL-104 cells directly into the tumor bed resulted in a significant increase in survival time compared with control animals. Therefore, local therapy with TALL-104 cells may be a novel and highly effective treatment approach for malignant brain tumors.
References
Blasberg, R.G., and Groothuis, D.R. (1986) Chemotherapy of brain tumors: Physiological and pharmacokinetic considerations. Semin. Oncol. 13, 70-82.[Web of Science][Medline]
Brenan, M., and Parish, C.R. (1984) Intracellular fluorescent labelling of cells for analysis of lymphocyte migration. J. Immunol. Methods 74,31 -38.[CrossRef][Web of Science][Medline]
Bullard, D.E., Bigner, S.H., and Bigner, D.D. (1985)
Comparison of intravenous versus intracarotid therapy with
1,3–bis(2–chloroethyl)-1–nitrosourea in a rat brain tumor
model. Cancer Res. 45,5240
-5245.
Cesano, A., and Santoli, D. (1992a) Two unique human leukemic T-cell lines endowed with a stable cytotoxic function and a different spectrum of target reactivity analysis and modulation of their lytic mechanisms. In Vitro Cell. Dev. Biol. 28A,648 -656.[CrossRef]
Cesano, A., and Santoli, D. (1992b) Inducible expression of granulocyte-macrophage colony-stimulating factor, tumor necrosis factor-a, and interferon-g in two human cytotoxic leukemic T cell lines. In Vitro Cell. Dev. Biol. 28A,657 -662.[CrossRef]
Cesano, A., Visonneau, S., Clark, S.C., and Santoli, D. (1993) Cellular and molecular mechanisms of activation of MHC non-restricted cytotoxic cells by IL-12. J. Immunol. 151,2943 -2957.[Abstract]
Cesano, A., Visonneau, S., Cioe, L., Clark, S.C., Rovera, G., and Santoli, D. (1994) Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach. J. Clin. Invest. 4,1076 -1084.
Cesano, A., Visonneau, S., and Santoli, D. (1995)
Treatment of experimental glioblastoma with a human major histocompatibility
complex nonrestricted cytotoxic T cell line. Cancer
Res. 55,96
-101.
Cesano, A., Visonneau, S., Jeglum, K.A., Owen, J., Wilkinson, K.,
Carner, K., Reese, L., and Santoli, D. (1996a) Phase I clinical
trial with a human major histocompatibility complex nonrestricted cytotoxic
T-cell line (TALL-104) in dogs with advanced tumors. Cancer
Res. 56,3021
-3029.
Cesano, A., Visonneau, S., Pasquini, S., Rovera, G., and Santoli,
D. (1996b) Antitumor efficacy of a human major histocompatibility
complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice
bearing syngeneic leukemia. Cancer Res.
56,4444
-4452.
Cesano, A., Pierson, G., Visonneau, S., Migliaccio, A.R., and
Santoli, D. (1996c) Use of a lethally irradiated major
histocompatibility complex nonrestricted cytotoxic T-cell line for effective
purging of marrows containing lysis-sensitive or -resistant leukemic targets.
Blood 87,393
-403.
Cesano, A., Visonneau, S., Deaglio, S., Malavasi, F., and Santoli,
D. (1998) Role of CD38 and its ligand in the regulation of
MHC-nonrestricted cytotoxic T cells. J. Immunol.
160,1106
-1115.
Cesano, A., Visonneau, S., Tran, T., and Santoli, D. (1999a) Biodistribution of human MHC non-restricted TALL-104 killer cells in healthy and tumor bearing mice. Int. J. Oncol. 14,245 -251.[Web of Science][Medline]
Cesano, A., Wortman, J.A., Pourdehnad, M., Visonneau, S., Mozley, D., Bhatnagar, A., Alavi, A., and Santoli, D. (1999b) Effects of development of host immunity on the biodistribution of xenogeneic MHC non-restricted cytotoxic T cells: Implications for adoptive cell therapy of cancer. Int. J. Oncol. 14,233 -244.[Web of Science][Medline]
Groothius, D.R., Vriesendorp, F.J., Kupfer, B., Warnke, P.C., Lapin, G.D., Kuruvilla, A., Vick, N.A., Mikhael, M.A., and Patlak, C.S. (1991) Quantitative measurements of capillary transport in human brain tumors by computed tomography. Ann. Neurol. 30,581 -588.[CrossRef][Web of Science][Medline]
Kornblith, P.L., and Walker, M. (1988) Chemotherapy for malignant gliomas. J. Neurosurg. 68, 1-17.[Web of Science][Medline]
Kurpad, S.N., Friedman, H.S., Archer, G.E., McLendon, R.E., Petros,
W.M., Fuchs, H.E., Guaspari, A., and Bigner, D.D. (1995)
Intraarterial administration of melphalan for treatment of intracranial human
glioma xenografts in athymic rats. Cancer Res.
55,3803
-3809.
Kurpad, S.N., Dolan, M.E., McLendon, R.E., Archer, G.E., Moschel, R.C., Pegg, A.E., Bigner, D.D., and Friedman, H.S. (1997) Intraarterial O6-benzylguanine enables the specific therapy of nitrosourea-resistant intracranial human glioma xenografts in athymic rats with 1,3–bis (2–chloroethyl)-1–nitrosourea. Cancer Chemother. Pharmacol. 39,307 -316.[CrossRef][Web of Science][Medline]
O'Connor, R., Cesano, A., Lange, B., Finan, J., Nowell, P.C.,
Clark, S.C., Raimondi, S.C., Rovera, G., and Santoli, D. (1991)
Growth factor requirements of childhood acute T-lymphoblastic leukemia:
Correlation between presence of chromosomal abnormalities and ability to grow
permanently in vitro. Blood
77,1534
-1545.
Ozols, R.F., Masuda, H., and Hamilton, T.C. (1988) Mechanisms of cross-resistance between radiation and antineoplastic drugs. NCI Monogr. 6,159 -165.
Packer, R.J., Sutton, L.N., Goldwein, J.W., Perilongo, G., Bunin, G., Ryan, J., Cohen, B.H., D'Angio, G., Kramer, E.D., Zimmerman, R.A., Rorke, L.B., Evans, A.E., and Schut, L. (1991) Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma. J. Neurosurg. 74,433 -440.[CrossRef][Web of Science][Medline]
Phillips, P.C. (1991) Antineoplastic drug resistance in brain tumors. Neurol. Clin. 9, 383-404.[Web of Science][Medline]
Rosenberg, S.A., Packard, B.S., Aebersold, P.N., Solomon, D., Topalian, S.L., Toy, S.T., Simon, P., Lotze, M.T., Yang, J.C., Seipp, C.A., Simpson, C., Carter, C., Bock, S., Schwartzentruber, D., Wei, J.P., and White, D.E. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Engl. J. Med. 319,1676 -1680.[Abstract]
Schuster, J.M., Friedman, H.S., Archer, G.E., Fuchs, H.E.,
McLendon, R.E., Colvin, O.M., and Bigner, D.D. (1993)
Intraarterial therapy of human glioma xenografts in athymic rats using
4–hydroperoxycyclophosphamide. Cancer Res.
53,2338
-2343.
Silverman, C.L., and Simpson, J.R. (1982) Cerebellar medulloblastoma: The importance of posterior fossa dose to survival and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys. 8,1869 -1876.[Web of Science][Medline]
Theron, J., Villemure, J.G., Worthington, C., and Tyler, J.L. (1986) Superselective intracerebral chemotherapy of malignant tumours with BCNU: Neuroradiological considerations. Neuroradiology 28,118 -125.[CrossRef][Web of Science][Medline]
Vick, N.A., Khandekar, J.D., and Bigner, D.D. (1977)
Chemotherapy of brain tumors: The "blood-brain barrier" is not a
factor. Arch. Neurol.
34,523
-526.
Visonneau, S., Cesano, A., Tran, T., Jeglum, K.A., and Santoli, D. (1997a) Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell TALL-104. Clin. Cancer Res. 3,1789 -1797.[Abstract]
Visonneau, S., Cesano, A., Torosian, M.H., and Santoli, D. (1997b) Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice. Clin. Cancer Res. 3,1491 -1500.[Abstract]
Visonneau, S., Cesano, A., Jeglum, K.A., and Santoli, D. (1999a) Adoptive therapy of canine mammary carcinoma with the human cytotoxic T cell line TALL-104. Oncol. Rep. 6,1181 -1188.[Web of Science][Medline]
Visonneau, S., Cesano, A., Jeglum, K.A., and Santoli, D.
(1999b) Adjuvant treatment of canine osteosarcoma with the human
cytotoxic T-cell line TALL-104. Clin. Cancer Res.
5,1868
-1875.
Whittington, R., and Faulds, D. (1993) Interleukin-2: A review of its pharmocological properties and therapeutic use in patients with cancer. Drugs 46,446 -514.[Web of Science][Medline]
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Brando, S. Mukhopadhyay, E. Kovacs, R. Medina, P. Patel, T. L. Catina, K. S. Campbell, and D. Santoli Receptors and lytic mediators regulating anti-tumor activity by the leukemic killer T cell line TALL-104 J. Leukoc. Biol., August 1, 2005; 78(2): 359 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. G. Gomez, S. B. Read, L. E. Gerschenson, D. Santoli, A. Zweifach, and C. A. Kruse Interactions of the allogeneic effector leukemic T cell line, TALL-104, with human malignant brain tumors Neuro-oncol, April 1, 2004; 6(2): 83 - 95. [Abstract] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
